Adapalene
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (November 2009) |
File:Adapalene.svg | |
Systematic (IUPAC) name | |
---|---|
6-[3-(1-adamantyl)-4-methoxy-phenyl] naphthalene-2-carboxylic acid | |
Clinical data | |
Pregnancy category |
|
Routes of administration | Topical |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Very low |
Excretion | Biliary |
Identifiers | |
CAS Number | 106685-40-9 |
ATC code | D10AD03 (WHO) |
PubChem | CID 60164 |
DrugBank | APRD00780 |
ChemSpider | 54244 |
Chemical data | |
Formula | C28H28O3 |
Molar mass | 412.52 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". | |
(verify) |
Adapalene is a third-generation topical retinoid primarily used in the treatment of mild-moderate acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions.[1] Adapalene is marketed by Galderma under the trade names Differin in some countries, Adaferin in India, and Epiduo. Epiduo also contains benzoyl peroxide.[2]
Contents
Indications
Adapalene is indicated for the topical treatment of acne vulgaris. It is possibly more effective than tretinoin 0.025% gel in the treatment of acne vulgaris.[citation needed]
History
Adapalene was approved in 1996 by the U.S. Food and Drug Administration (FDA) for use in the treatment of acne.[citation needed]
Dosage
Adapalene is applied once daily, after washing and before retiring. In some circumstances, when a patient complains of skin irritation, the application may be decreased to once every other day until the irritation ceases. The prescribing doctor may also recommend washing the applied areas with soap and water a specified period after usage to reduce irritation.[citation needed]
Available forms
In the United States, adapalene is available under the brand name Differin in three different preparations: 0.1% cream, 0.1% gel, and 0.3% gel.[3] In Europe, only the 0.1% cream and 0.1% gel are available. In Pakistan, adapalene is available under the brand names Clear by Saffron Pharmaceuticals and Gallet by Pharma Health Pakistan, both of these are in the form of 0.1% cream. In India it it available under the trade name Adelene with 0.1 % Adapalene and 1 % Clindamycin phosphate.[citation needed]
Pharmacology
Drug interactions
Adapalene has been shown to enhance the efficacy of topical clindamycin, although adverse effects are also increased.[4] Application of adapalene gel to the skin 3–5 minutes before application of clindamycin enhances penetration of clindamycin into the skin, which may enhance the overall efficacy of the treatment as compared to clindamycin alone.[5]
Unlike tretinoin (Retin-A), adapalene has also been shown to retain its efficacy when applied at the same time as benzoyl peroxide due to its more stable chemical structure.[6]
Pharmacodynamics
Adapalene in small concentrations is a moderator of cellular differentiation, keratinization, and inflammatory processes. It has both exfoliating and anti-inflammatory effects. The exact mode of action of adapalene is unknown.
Pharmacokinetics
Adapalene is applied topically to the skin, and its absorption into the blood through this medium is very low. Only trace amounts of adapalene have been found in the plasma of chronically treated patients.[citation needed]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Differin product insert
- Adapalene General Information, Patient Information, Contraindications and Interactions
- [www.epiduo.com/Includes/PDF/BriefSummary.pdf Epiduo Prescribing Information]
fr:Adapalène it:Adapalene nl:Adapaleen ja:アダパレン pl:Adapalen
pt:Adapaleno- ↑ Rolewski S (2003). "Clinical review: topical retinoids". Dermatol Nurs. 15 (5): 447–50, 459–65. PMID 14619325.
- ↑ (Patient Drug Information, uptodate.com, August 2009)
- ↑ About Differin
- ↑ Wolf JE, Kaplan D, Kraus SJ; et al. (2003). "Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study". J Am Acad Dermatol. 49 (3 Suppl): S211–7. doi:10.1067/S0190-9622(03)01152-6. PMID 12963897.
- ↑ Jain GK, Ahmed FJ (2007). "Adapalene pretreatment increases follicular penetration of clindamycin: in vitro and in vivo studies". Indian J Dermatol Venereol Leprol. 73 (5): 326–9. doi:10.4103/0378-6323.34010. PMID 17921613.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Articles needing additional references from November 2009
- Articles with invalid date parameter in template
- All articles needing additional references
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- All articles with unsourced statements
- Articles with unsourced statements from July 2010
- Retinoids
- Carboxylic acids
- Anti-acne preparations
- Naphthalenes
- Adamantanes
- Phenol ethers
- Acne treatments
- 2Fix
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list